VTRS

Viatris (VTRS) has agreed to acquire Pacira BioSciences (PCRX) for $1.65 billion in cash at $36.50 per share, expected to close by end of 2026. The acquisition adds two marketed pain therapies (Exparel and Zilretta) generating $350.5 million in H1 2026 sales, plus a mid-stage gene therapy candidate (PCRX-201) for knee osteoarthritis. The deal is expected to be immediately accretive to Viatris' financial metrics and strengthen its non-opioid pain management portfolio.

A comparison of two Medical Services sector stocks, Viatris (VTRS) and Avantor (AVTR), both holding a Zacks Rank #2 (Buy) rating. Based on valuation metrics including forward P/E ratio (7.01 vs 19.51), PEG ratio (1.92 vs 11.93), and P/B ratio (1.44 vs 1.9), Viatris emerges as the superior value opportunity with a Value grade of A compared to Avantor's C grade.

Viatris (VTRS) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating with an 'A' Value grade. The stock demonstrates undervaluation across multiple metrics including a P/B ratio of 0.75 (below industry average of 2.17), P/S ratio of 1.37 (below industry average of 1.54), and P/CF ratio of 5.21 (significantly below industry average of 11.92), suggesting solid cash flow and earnings outlook.